8-K: Xtant Medical Reports Q1 2026 Results, Raises Guidance

Xtant Medical Holdings, Inc. announced its first quarter 2026 financial results, reporting a net loss of $3.1 million and raising its full-year revenue guidance to $101-$105 million.

Summary

• Xtant Medical Holdings, Inc. reported first quarter 2026 revenue of $20.9 million, a decrease from $32.9 million in the prior year period, primarily due to asset sales and non-recurring license revenue.
• The company experienced a net loss of $3.1 million for the quarter, compared to a net income of $58,000 in Q1 2025.
• Non-GAAP adjusted EBITDA was a loss of $1.6 million, down from a positive $3.0 million in the prior year.
• Total indebtedness was reduced by $13.3 million, with $10.4 million paid down on the revolving line of credit and $2.8 million on the term loan.
• Full-year 2026 revenue guidance has been increased to $101 million - $105 million, up from $95 million - $99 million, driven by the new HEMOBLAST Bellows distribution agreement.
• The company finalized the sale of its Coflex/CoFix assets and international hardware business to Companion Spine, receiving the final $10.7 million payment.
• An exclusive U.S. distribution agreement was signed for Dilon Technologies' HEMOBLAST Bellows product, and Xtant hired Dilon's U.S. sales team.
• The company launched Trivium Shaped, a new demineralized bone matrix allograft.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the company is strengthening its balance sheet and raising revenue guidance due to a new distribution agreement, the significant year-over-year decline in revenue, shift to a net loss, and negative adjusted EBITDA in the current quarter are concerning.

Positives

• Increased full-year 2026 revenue guidance to $101 million - $105 million, reflecting strong growth expectations.
• Significantly strengthened the balance sheet by reducing total indebtedness by $13.3 million.
• Secured an exclusive U.S. distribution agreement for the HEMOBLAST Bellows hemostatic product, expanding into a multi-billion dollar market.
• Successfully integrated Dilon's approximately 20-person U.S. sales team, enhancing commercial capabilities.
• Finalized the sale of non-core assets to Companion Spine, receiving the full $21.4 million purchase price.
• Launched Trivium Shaped, an innovative extension of its demineralized bone matrix allograft product line.

Negatives

• First quarter 2026 revenue decreased to $20.9 million from $32.9 million in Q1 2025, primarily due to divestitures and non-recurring license revenue.
• Reported a net loss of $3.1 million for the first quarter of 2026, a significant shift from a net income of $58,000 in the prior year.
• Non-GAAP adjusted EBITDA turned negative, showing a loss of $1.6 million in Q1 2026 compared to a positive $3.0 million in Q1 2025.
• Gross margin decreased to 57.3% from 61.5% due to the cessation of high-margin license revenue.

Risks

• The success of the HEMOBLAST Bellows distribution agreement and its impact on future U.S. sales and operating results.
• Potential termination of the distribution agreement by either party.
• The effect of the distribution agreement on relationships with other distributors and independent sales representatives.
• The ability of the expanded field sales force to improve the company's reach and leverage its contract portfolio.
• Risks associated with acquisitions and dispositions, including integration challenges.
• Potential future impairment charges to long-lived assets and goodwill, and write-downs of excess inventory.
• The ability to obtain and maintain regulatory approvals and comply with government regulations.
• Product liability claims, litigation, product recalls, and defects.

Future Outlook

The company has raised its full-year 2026 revenue guidance to a range of $101 million to $105 million, an increase from the previous guidance of $95 million to $99 million. This upward revision is attributed to the anticipated incremental revenue from the recently licensed Dilon Technologies HEMOBLAST Bellows product.

Management Comments

• "The first quarter of 2026 and subsequent period were pivotal for Xtant."
• "Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category."
• "We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilons 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond."
• "These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio."

Industry Context

StockSavvy.ai notes that Xtant Medical's strategic move to acquire U.S. distribution rights for the HEMOBLAST Bellows product and integrate Dilon's sales team signifies a push into the high-growth hemostatics market, a segment often characterized by significant revenue potential and competitive dynamics. This diversification aims to offset revenue declines from divested assets and non-recurring items, aligning with broader industry trends of consolidation and strategic partnerships to gain market share and expand product portfolios.

Comparison to Industry Standards

• The reported Q1 2026 revenue of $20.9 million is lower than Q1 2025's $32.9 million, which is a significant year-over-year decline. While this is explained by divestitures, it contrasts with companies in the medical technology sector that are experiencing growth through organic product development or strategic acquisitions.
• The shift from a net income of $58,000 in Q1 2025 to a net loss of $3.1 million in Q1 2026, and a decline in adjusted EBITDA from $3.0 million to a loss of $1.6 million, indicates a challenging operational period. This performance is below the profitability benchmarks often seen in established medical device companies.
• The increased full-year revenue guidance to $101-$105 million suggests a strong recovery and growth trajectory for the remainder of 2026, which, if achieved, would align with industry expectations for companies successfully integrating new product lines and distribution channels.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased revenue guidance and new distribution agreement are positive indicators for future growth, but the current net loss and decreased revenue may cause concern. The deadlines for annual meeting proposals impact their ability to influence corporate actions.
• Employees: The hiring of Dilon's sales team suggests potential for increased employment and opportunities within Xtant Medical, particularly in sales roles.
• Suppliers: The divestiture of certain assets may impact relationships with suppliers previously serving those businesses.
• Creditors: The reduction in total indebtedness by $13.3 million strengthens the company's financial position, potentially improving its standing with creditors.

Next Steps

• The company will host a webcast and conference call on May 13, 2026, at 8:30 am ET to discuss Q1 2026 results.
• Stockholders must submit proposals for inclusion in the 2026 Annual Meeting proxy materials by May 23, 2026.
• Stockholders must submit other proposals and director nominations by May 23, 2026.
• Stockholders intending to solicit proxies for director nominees must provide notice by June 9, 2026.

Key Dates

Recommendation

The company is making strategic moves to expand its market reach and revenue potential with the HEMOBLAST Bellows distribution agreement and has raised its full-year guidance. However, the significant year-over-year decline in revenue, the shift to a net loss, and the negative adjusted EBITDA in the current quarter present considerable risks. A 'hold' recommendation is appropriate pending further evidence of sustained revenue growth and a return to profitability.

Keywords

Xtant Medical, 8-K, Financial Results, Revenue Guidance, HEMOBLAST Bellows, Medical Technology, Orthopedics, Spinal Solutions